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Introduction
Malignant pleural effusion is a much-feared
complication of many cancers. In addition to carrying a
poor prognosis, it is often accompanied by such
symptoms as cough, chest pain, and shortness of breath
that diminish the patient’s quality of life. Bronchogenic
cancer accounts for a third of malignant pleural
effusions, followed in frequency by breast cancer;
lymphoma; and, less commonly, malignant pleural
mesothelioma and others.1-3 Mean survival in such
patients does not usually exceed 6 months.4 The
management of malignant pleural effusion, therefore,
requires a palliative approach to relieve pain and allow
symptoms to be controlled in the least aggressive and
most effective way possible while shortening hospital
stays.
Several techniques are available for the management
of malignant pleural effusion. Repeated thoracentesis,
although easy to perform and generally free of
complications, is not the ideal approach, as in many
cases the reaccumulation of fluid takes place within a
very short time (as few as 4 days).5 For this reason, the
usual approach is the placement of a conventional
thoracostomy tube followed by talc slurry pleurodesis,
or in some cases, the use of video-assisted
thoracoscopic talc insufflation. Both therapeutic
options, while very effective, are not free from
complications and generally require hospitalization,
which in some cases may exceed 10 days.
The development of several small caliber pleural
catheters has opened the door to new strategies for the
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Inpatient management of malignant pleural effusion
includes the placement of a conventional thoracostomy tube
for drainage and talc slurry pleurodesis and/or a surgical
approach consisting of video-assisted thoracoscopic talc
insufflation. Both techniques require prolonged hospital
stays of up to 1 week. Unfortunately, life expectancy in
patients with this disease does not usually exceed 6 months,
and so the primary aim of any palliative intervention
intended to improve quality of life should be to avoid
hospital admissions and to relieve pain as far as possible.
Of the few outpatient alternatives to hospital management
the most frequently used is repeated thoracentesis. We
describe the outpatient management of malignant pleural
effusion by placement of a tunneled pleural catheter in a
patient with stage IIIB lung adenocarcinoma. In our
opinion, the use of this catheter offers a viable alternative to
conventional therapy and is better tolerated.
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Manejo ambulatorio del derrame pleural maligno 
mediante colocación de un catéter de drenaje
tunelizado. Experiencia preliminar
El manejo hospitalario del derrame pleural maligno in-
cluye la colocación de un tubo de toracostomía convencio-
nal, drenaje y esclerosis mediante talcaje, y/o el abordaje
quirúrgico mediante videotoracoscopia. Ambas técnicas re-
quieren ingresos prolongados, de hasta una semana de du-
ración. Lamentablemente, la esperanza de vida en pacientes
con esta enfermedad no suele superar los 6 meses, motivo
por el que toda intervención paliativa destinada a mejorar
la calidad de vida debe tener como objetivo primordial el
evitar, en la medida de lo posible, el ingreso hospitalario y
aliviar el dolor.
Hay pocas alternativas ambulatorias al manejo hospitala-
rio. De ellas, la toracocentesis de repetición es la más fre-
cuentemente utilizada. Describimos el uso de un catéter tu-
nelizado en el manejo ambulatorio del derrame pleural
maligno de un paciente con adenocarcinoma de pulmón en
estadio IIIB. Consideramos que este catéter ofrece una al-
ternativa viable y mejor tolerada que el tratamiento conven-
cional.
Palabras clave: Derrame pleural maligno. Catéter tunelizado.
Manejo ambulatorio.
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treatment of malignant pleural effusion with minimal
associated morbidity, making outpatient management
possible in some cases.6-9 Several studies have shown
the palliative efficacy of such catheters, which are
associated with lower costs, shorter hospital stays, and
reduced pain.10-12
Case Description
We report the case of a 77-year old non-smoking woman
diagnosed with stage IIIB lung adenocarcinoma with
malignant pleural effusion. Although she initially responded to
treatment with erlotinib, reaccumulation of pleural fluid was
observed in February 2005 (Figure 1A). The effusion was
associated with irritating dry cough and dyspnea that
progressed until it appeared even on minimal effort. In the
physical examination the most noteworthy findings were
resting arterial oxygen saturation as measured by pulse
oximetry of 95% and dullness to percussion at the base of the
right lung with loss of normal vesicular sounds in a large part
of this hemithorax. A chest x-ray taken in April showed
clinically significant right pleural effusion and for that reason
we chose to place a Pleurx pleural catheter (Denver
Biomedical Inc, Golden, Colorado, USA) (Figures 1B and
1C). Catheter placement, performed under sedation (2.5 mg of
midazolam) and local anesthesia after informed consent had
been obtained, was uneventful. We drained 1100 mL of
serosanguineous fluid and a family member was trained in
how to use the device correctly under aseptic conditions in
order to drain the pleural fluid at home every 2 to 3 days. The
catheter was well tolerated by the patient, who hardly noticed
its presence and did not experience dyspnea in the weeks
following placement, although she did experience mild chest
pain that responded to prescribed analgesic therapy. Once the
quantity of fluid extracted had decreased to less than 50 mL on
3 consecutive occasions, we decided to remove the catheter 1
month after placement, after a computed tomography (CT)
scan of the thorax confirmed the absence of effusion. 
Another CT scan performed 2 months after the removal of
the catheter (Figure 1D) showed only residual pleural
thickening, with no reaccumulation of fluid. The patient died a
few months later of causes unrelated to her respiratory disease,
with no evidence of reaccumulation of fluid or dyspnea.
Discussion
The Pleurx catheter (Figure 2), like other similar
ones, makes the reliable management of any malignant
pleural effusion possible without hospitalization. The
greatest advantage of this catheter is that it is tunneled
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Figure 1. The computed tomography (CT) scan performed in April showed a large right-sided pleural effusion (A). Cytology confirmed the presence of
tumor cells. The CT scan performed in May (B and C) showed a decrease in the amount of fluid. The arrows indicate the pleural drainage site. Two
months after removal of the catheter (D) it was confirmed that there was no reaccumulation of pleural fluid. Talc slurry pleurodesis was not necessary.
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and thus allows the patient to engage in normal
activities with minimal risk of infection. The placement
of this catheter requires no more than 20 minutes and
allows pleural fluid to be drained at home. Various
studies in the literature describe such adverse effects as
the appearance of superficial skin infections (limited to
the insertion site); mild chest pain; and, exceptionally,
the tumor growth along the tunnel path. We describe
our first clinical experience with the placement of a
Pleurx catheter in Spain. As has been shown in other
studies, the complications associated with the
placement and handling of this catheter are minimal.
Chemical sclerosis is unnecessary in up to 58% of
cases, as sclerosis is achieved spontaneously in an
average of 39 days.13 The placement, handling, and later
removal of the catheter are carried out on an outpatient
basis. The Pleurx catheter has been shown to relieve the
symptoms of dyspnea associated with malignant pleural
effusion in all patients, regardless of whether or not
sclerosis has been achieved.13 In addition to being better
tolerated, the device is clearly associated with lower
costs than conventional therapeutic options which
require hospitalization ($3392 compared to $7830).14 A
phase III clinical trial sponsored by the US National
Cancer Institute (NCT00042770), designed to compare
the efficacy of conventional thoracostomy with
outpatient handling of malignant pleural effusion
through the placement of tunneled catheters, is now
underway. In that trial, the short- or medium-term
impact of each therapeutic option on patients’ quality of
life, oxygenation, and control or eradication of the
pleural effusion is being analyzed.13
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Figure 2. The Pleurx tunneled
catheter (Denver Biomedical Inc,
Golden, Colorado, USA) and a bottle
for home drainage.
09 ing660-662 NOT 5211.qxd  12/12/06  11:45  Página 662
